Drug Trial Radar · NCT05093933
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
Last checked: Nov 20, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,106
Actual
Start
Nov 2, 2021
Primary completion
Nov 20, 2024
Study completion Feb 5, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had a recent hospitalization for heart failure or need for outpatient intravenous (IV) diuretics. The primary hypothesis is that vericiguat is superior to placebo in reducing the risk of cardiovascular death or heart failure hospitalization.
Conditions
- Chronic Heart Failure With Reduced Ejection Fraction
Interventions
VericiguatDrug
2.5, 5.0, or 10.0 mg orally once daily
PlaceboDrug
0 mg matching placebo for 2.5 mg, 5 mg, and 10 mg of vericiguat
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization: Participants With an Event Per 100 Patient-YearsTime frame: Up to approximately 36 months (from randomization to the primary completion data cutoff)
Locations
519 sites in 36 countries. Site status is shown where the registry gives one.
Advanced Cardiovascular - Alexander City ( Site 0038)
Alexander City, Alabama
University of Alabama at Birmingham - School of Medicine-Cardiology ( Site 0153)
Birmingham, Alabama
Heart Center Research, LLC ( Site 0156)
Huntsville, Alabama
Mercy Gilbert Medical Center-Dignity Health Cardiology ( Site 0075)
Gilbert, Arizona
Valley Clinical Trials, Inc. ( Site 0085)
Covina, California
VA West Los Angeles Medical Center-Cardiology ( Site 0149)
Los Angeles, California
Valley Clinical Trials Inc ( Site 0006)
Northridge, California
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center ( Site 0010)
Torrance, California
Blue Coast Research Center ( Site 0053)
Vista, California
Excel Medical Clinical Trials ( Site 0008)
Boca Raton, Florida
Universal Axon Clinical Research, LLC ( Site 0022)
Doral, Florida
Holy Cross Hospital ( Site 0100)
Fort Lauderdale, Florida
Indago Research and Health Center Inc ( Site 0011)
Hialeah, Florida
South Florida Research Solutions ( Site 0058)
Hollywood, Florida
University of Florida - Jacksonville ( Site 0169)
Jacksonville, Florida
East Coast Institute for Research, LLC ( Site 0047)
Jacksonville, Florida
Cardiovascular Research Center of South Florida ( Site 0074)
Miami, Florida
ProLive Medical Research ( Site 0032)
Miami, Florida
Peace River Cardiovascular Center ( Site 0088)
Port Charlotte, Florida
BAYCARE MEDICAL GROUP ( Site 0099)
Safety Harbor, Florida
East Coast Institute for Research - St. Augustine ( Site 0016)
Saint Augustine, Florida
Cardiovascular Center of Sarasota ( Site 0154)
Sarasota, Florida
Emory University School of Medicine ( Site 0123)
Atlanta, Georgia
IACT Health ( Site 0106)
Columbus, Georgia
NSC Research ( Site 0068)
Johns Creek, Georgia
Georgia Arrhythmia Consultants and Research Institute ( Site 0042)
Macon, Georgia
Cardiovascular Consultants of South Georgia, LLC ( Site 0137)
Thomasville, Georgia
Mount Sinai Hospital ( Site 0050)
Chicago, Illinois
Chicago Medical Research ( Site 0086)
Hazel Crest, Illinois
OSF Healthcare Cardiovascular Institute ( Site 0122)
Peoria, Illinois
Methodist Medical Center of Illinois ( Site 0098)
Peoria, Illinois
Franciscan Physician Network - Indiana Heart Physicians ( Site 0087)
Indianapolis, Indiana
The Heart Center of Lake County Research Institute-Research ( Site 0147)
Merrillville, Indiana
Cardiovascular Research of Northwest Indiana ( Site 0036)
Munster, Indiana
Reid Physician Associates ( Site 0054)
Richmond, Indiana
University of Iowa ( Site 0005)
Iowa City, Iowa
Alliance for Multispecialty Research, LLC ( Site 0143)
Wichita, Kansas
Norton Healthcare-Norton Heart Specialist ( Site 0062)
Louisville, Kentucky
Cambridge Medical Trials ( Site 0041)
Alexandria, Louisiana
Louisiana Heart Center - Hammond ( Site 0004)
Hammond, Louisiana
Showing 40 of 519 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.